Posted on June 19, 2014
The Colon Cancer Alliance is committed to providing support and empowerment to those who are affected by colon cancer. This is why we’re actively addressing the patient impact of high out-of-pocket costs for medicine when it comes to the Affordable Care Act (ACA) and exchange coverage. We continue to hear the stories: due to increased costs, many patients are making decisions about treatment based on financial implication as opposed to selecting the best treatment path to address their current condition. Read more
Posted on April 5, 2014
While we often say that the colonoscopy is the “gold standard” when it comes to colon cancer screening, no test is perfect. But colonoscopy still offers the most effective screening option.
A recent study by the Huntsman Cancer Institute at the University of Utah found that about 6% of colon cancers are diagnosed within three to five years after a patient receives a clean colonoscopy. Read more
Posted on March 28, 2014
We support the latest advancements in screening for colon cancer and are at the pulse of the FDA approval process for products that will help save lives and prevent colon cancer. On Thursday, our CEO, Eric Hargis, attended the FDA hearing to make a statement in support of Cologuard, a new, cutting-edge stool DNA test. This non-invasive colon cancer screening test created by Exact Sciences went in front of the FDA’s Molecular and Clinical Genetics Panel of Medical Devices Advisory Committee. Read more
Posted on March 26, 2014
A colonoscopy remains the best available procedure for detecting and removing pre-cancerous polyps; however, due to both technique and viewing area, studies have shown that some polyps may be missed. EndoChoice has developed a new colonoscope called Full Spectrum Endoscopy™ (Fuse™) that uses multiple cameras to create a panoramic view, allowing GIs to see more of the tract.
Posted on March 25, 2014
Living with cancer takes a toll on anyone, but it can be especially devastating for uninsured and low-income patients. That’s why the 340B Drug Pricing Program is such an important issue. Congress created this program in 1992 to help improve access to medical services for this population. The program works by providing discounted prescription drugs to hospitals and clinics that serve high numbers of uninsured, low-income patients. Since the program’s creation, however, concerns have grown about whether the 340B program has strayed from its original purpose. Read more